Search

Displaying results 301 - 310 of 4539 in total
  1. Drug

    Avalglucosidase alfa

    go.drugbank.com/drugs/DB16099
    ApprovedInvestigational

    [L35160] Avalglucosidase alfa was approved by Health Canada on November 15, 2021 for the treatment of patients older than six months of age with late-onset Pompe disease. … [A232960] On August 6, 2021, avalglucosidase alfa-ngpt was approved by the FDA under the market name Nexviazyme to treat patients one year of age and older with late-onset Pompe disease.

  2. Drug

    Zomepirac

    go.drugbank.com/drugs/DB04828
    ApprovedWithdrawn

    The manufacturer voluntarily removed Zomax tablets from the Canadian, US, and UK markets in March 1983.

  3. Drug

    Tozinameran

    go.drugbank.com/drugs/DB15696
    ApprovedInvestigational

    [A225386] Comirnaty was granted a EUA in the UK on December 2, 2020,[L26676] and in Canada on December 9, 2020[L26671] for active immunization against SARS-CoV-2. … [L15017, L15022] Comirnaty received fast track designation by the U.S. FDA on July 13, 2020.

  4. Drug

    Ozenoxacin

    go.drugbank.com/drugs/DB12924
    Approved

    and older. … s Xepi (ozenoxacin 1%) as a topically applied cream indicated for the treatment of impetigo caused by *Staphylococccus aureus* or *Streptococcus pyogenes* in adult and pediatric patients 2 months of age

  5. Drug

    Ethylhexyl methoxycrylene

    go.drugbank.com/drugs/DB11226
    Approved

    Ethylhexyl methoxycrylene is a photostabilizer that preserves the effectiveness of UV filters by interacting with both the singlet and triplet states [F104]. … It returns UV filters to their ground states without absorbing sunlight [F104].

  6. Drug

    Teplizumab

    go.drugbank.com/drugs/DB06606
    ApprovedInvestigational

    Teplizumab was designed as an Fc-non-binding antibody in order to reduce the incidence of CRS. … [A241490] Anti-CD3 therapy has traditionally been used to prevent graft-versus-host-disease in organ transplantation but more recently has been explored to prolong the onset of (T1D) in high-risk patients

  7. Drug

    Garadacimab

    go.drugbank.com/drugs/DB15629
    Approved

    [A273993] In June 2025, garadacimab was approved by the US FDA for the prophylaxis of HAE episodes in patients ≥12 years of age. … [L53283,A273998] Garadacimab received its first approval in Australia and the UK in January 2025, and has since been approved in a number of other jurisdictions, including the EU and Japan.

  8. Drug

    Azithromycin

    go.drugbank.com/drugs/DB00207
    ApprovedInvestigational

    It was initially approved by the FDA in 1991 [A174175]. … In March 2020, a small study was funded by the French government to investigate the treatment of COVID-19 with a combination of azithromycin and the anti-malaria drug [hydroxychloroquine].

    Products: ZITHROMAX TR-SAFT K B 25KG, AZITROMICINA MK 200 MG/ 5 ML POLVO PARA SUSPENSION
  9. Drug

    Carbidopa

    go.drugbank.com/drugs/DB00190
    ApprovedInvestigational

    [L5110] On the other hand, the combination treatment of carbidopa/levodopa was originally developed by Watson Labs but the historical information by the FDA brings back to the approval of this combination … therapy developed by Mayne Pharma in 1992.

  10. Drug

    Ecamsule

    go.drugbank.com/drugs/DB09534
    Approved

    Ecamsule has been approved for use in the U.S. since 2006, but only at a specific concentration and only in a few products manufactured by L'Oreal.

    Mixtures: Hydraphase Uv, Rosaliac Uv